Trial · NCT04334915
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
NCT04334915, Phase 2, Withdrawn, National Institute of Allergy and Infectious Diseases (NIAID)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV. Trials, record NCT04334915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04334915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
- NCT number
- NCT04334915
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- HIV Infections
- Interventions
- Cenicriviroc Mesylate (CVC), Placebo
- First posted
- 2020-04-06
- Last updated
- 2022-12-21
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in arterial most diseased segment (MDS) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) target-to-background ratio (TBR), measured in the carotid arteries and aorta. | Pre-entry and week 24 | The standardized uptake value (SUV) of FDG will be measured in the carotid arteries, aortic root, and the left main coronary artery. The SUV is the decay-corrected tissue concentration of FDG (in kBq/mL) divided by the injected dose per body weight (kBq/g). TBR will be calculated for each vascular segment as the segment SUV divided by mean venous blood SUV. Change from baseline to week 24, where baseline is defined as pre-entry. |
| Secondary | Change in aortic TBR (and other TBRs) | Pre-entry and week 24 | Target-to-background ratio (TBR) will be calculated for each vascular segment as the segment standardized uptake value (SUV) divided by mean venous blood SUV. Change from baseline to week 24, where baseline is defined as pre-entry. |
| Secondary | Change in SUV measured in the carotid arteries and aorta | Pre-entry and week 24 | The standardized uptake value (SUV) is the decay-corrected tissue concentration of fluorodeoxyglucose (FDG) (in kBq/mL) divided by the injected dose per body weight (kBq/g). Change from baseline to week 24, where baseline is defined as pre-entry. |
| Secondary | Change in fasting glucose | Entry and week 24 | Change from baseline to week 24, where baseline is defined as entry. |
| Secondary | Change in HOMA-IR | Entry and week 24 | Change from baseline to week 24, where baseline is defined as entry. |
| Secondary | Change in sCD14 | Pre-entry, entry, week 22, and week 24 | Change from baseline to week 22/24, where baseline is defined as the average of pre-entry and entry values, and week 22/24 is defined as the average of week 22 and week 24 values. |
| Secondary | Change in sCD163 | Pre-entry, entry, week 22, and week 24 | Change from baseline to week 22/24, where baseline is defined as the average of pre-entry and entry values, and week 22/24 is defined as the average of week 22 and week 24 values. |
| Secondary | Change in IL-6 | Pre-entry, entry, week 22, and week 24 | Change from baseline to week 22/24, where baseline is defined as the average of pre-entry and entry values, and week 22/24 is defined as the average of week 22 and week 24 values. |
| Secondary | Change in hsCRP | Pre-entry, entry, week 22, and week 24 | Change from baseline to week 22/24, where baseline is defined as the average of pre-entry and entry values, and week 22/24 is defined as the average of week 22 and week 24 values. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04334915
GET https://conductscience.org/api/trials/v1/NCT04334915/registered